...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Top-Line Data Expected September 2019 for BETonMACE Phase 3 Cardiovascular Outcomes Trial for Apabetalone

Free
Message: Low Impact Journals

Thanks. Never thought that IF might not be a big consideration for industry. I am a physician who publishes frequently and IF is a big consideration as to where I sent my research.

Share
New Message
Please login to post a reply